SCHEMBL4994619

SCHEMBL4994619

CC1CC(C)CN(c2ccc(NC=C3C(=O)Nc4cccc(F)c43)cc2F)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.33
PDGFRB P09619 3/20 0.33
EGFR P00533 1/20 0.33
PDGFRA P16234 1/20 0.33
KDR P35968 1/20 0.33
RET P07949 2/20 0.32
ERBB2 P04626 1/20 0.32
PIM2 Q9P1W9 4/20 0.32
NPC1 O15118 1/20 0.32
NTRK1 P04629 2/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
IGF1R P08069 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
KDM1A O60341 1/20 0.31
PIM1 P11309 2/20 0.31
TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994616 1.00 POLB (0.33) POLBPDGFRBEGFRPDGFRAKDR
SCHEMBL4988976 0.93 PDGFRB (0.35) POLBPDGFRBEGFRPDGFRAKDR
SCHEMBL4988974 0.93 PDGFRB (0.35) POLBPDGFRBEGFRPDGFRAKDR
SCHEMBL4990695 0.91 NTRK1 (0.36) POLBPDGFRBEGFRPDGFRAKDR
SCHEMBL4990689 0.91 NTRK1 (0.36) POLBPDGFRBEGFRPDGFRAKDR
SCHEMBL4993929 0.90 GHSR (0.36) PDGFRBEGFRPDGFRAKDRTYK2
SCHEMBL4993923 0.90 GHSR (0.36) PDGFRBEGFRPDGFRAKDRTYK2
SCHEMBL4996493 0.90 PDE3B (0.42) PDGFRBEGFRPDGFRAKDRRET
SCHEMBL4996497 0.90 PDE3B (0.42) PDGFRBEGFRPDGFRAKDRRET
SCHEMBL4995407 0.89 HTT (0.40) POLBPIM2PIM1TYK2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 POLB 2450/4885PDGFRB 307/4885EGFR 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.